# CGT1145

Type: drug

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/cgt1145
Canonical HTML page: https://getbiobrief.com/entity/cgt1145

## Recent coverage (1 stories)

### Cogent’s CGT1145 Hits 100x JAK2 Selectivity, IND Filing Next for Rare Cancer Drug
2026-07-12 10:29:51 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

The biotech’s novel inhibitor could redefine the JAK2-targeted therapy landscape, with preclinical data supporting disease-modifying potential ahead of a planned IND submission this year. Investors watch for Phase 1 timing.
Full story: https://getbiobrief.com/story/cogent-cgt1145-100x-jak2-selectivity-ind-filing

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.